{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urothelial+Carcinoma+Bladder&page=13", "query": { "condition": "Urothelial Carcinoma Bladder", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 457, "total_pages": 46, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urothelial+Carcinoma+Bladder&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urothelial+Carcinoma+Bladder&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T15:16:51.052Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01454089", "title": "A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urologic Neoplasms", "Metastatic Bladder Cancer", "Urinary Tract Neoplasms" ], "interventions": [ { "name": "OGX-427 600 mg", "type": "DRUG" }, { "name": "OGX-427 1000 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Achieve Life Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 183, "start_date": "2011-10", "completion_date": "2014-11", "has_results": false, "last_update_posted_date": "2016-10-07", "last_synced_at": "2026-10-14T15:16:51.052Z", "location_count": 14, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 9 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01454089" }, { "nct_id": "NCT03912818", "title": "Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Adenocarcinoma", "Bladder Mixed Adenocarcinoma", "Bladder Squamous Cell Carcinoma", "Bladder Urothelial Carcinoma", "Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant", "Infiltrating Bladder Urothelial Carcinoma With Giant Cells", "Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation", "Infiltrating Bladder Urothelial Carcinoma With Trophoblastic Differentiation", "Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant", "Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant", "Infiltrating Bladder Urothelial Carcinoma, Nested Variant", "Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Cystectomy", "type": "PROCEDURE" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Vinblastine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2019-04-10", "completion_date": "2022-08-11", "has_results": true, "last_update_posted_date": "2023-09-11", "last_synced_at": "2026-10-14T15:16:51.052Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03912818" }, { "nct_id": "NCT01234519", "title": "A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Urothelial Carcinoma" ], "interventions": [ { "name": "AEZS-108", "type": "DRUG" }, { "name": "AEZS-108 at MTD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AEterna Zentaris", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2010-11", "completion_date": "2014-11", "has_results": false, "last_update_posted_date": "2018-03-15", "last_synced_at": "2026-10-14T15:16:51.052Z", "location_count": 2, "location_summary": "Miami, Florida • Philadelphia, Pennsylvania", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01234519" }, { "nct_id": "NCT06417190", "title": "Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Muscle-Invasive Bladder Carcinoma", "Tumor" ], "interventions": [ { "name": "Trimodal therapy (TMT) within 45 days of neoadjuvant chemotherapy (NAC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Leslie Ballas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2026-01-16", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-10-14T15:16:51.052Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06417190" }, { "nct_id": "NCT00238420", "title": "Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Bladder Urothelial Carcinoma", "Stage I Bladder Cancer AJCC v6 and v7", "Stage II Bladder Cancer AJCC v6 and v7", "Stage III Bladder Cancer AJCC v6 and v7" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2005-07-26", "completion_date": "2022-05-20", "has_results": true, "last_update_posted_date": "2022-07-19", "last_synced_at": "2026-10-14T15:16:51.052Z", "location_count": 180, "location_summary": "Mobile, Alabama • Anchorage, Alaska • Auburn, California + 115 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Auburn", "state": "California" }, { "city": "Burbank", "state": "California" }, { "city": "Cameron Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00238420" }, { "nct_id": "NCT02717156", "title": "Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage IV Bladder Urothelial Carcinoma", "Prostate Cancer", "Urothelial Carcinoma" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Recombinant EphB4-HSA Fusion Protein", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "OTHER", "BIOLOGICAL" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2016-11-21", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-06-09", "last_synced_at": "2026-10-14T15:16:51.052Z", "location_count": 9, "location_summary": "Duarte, California • Los Angeles, California • Newport Beach, California + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02717156" }, { "nct_id": "NCT07726602", "title": "Tumor-informed ctDNA in Muscle-invasive Bladder Cancer for Evaluation of Residual/Recurrent Disease - the TiMBER Trial", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Muscle Invasive Bladder Urothelial Carcinoma", "Stage II Bladder Cancer AJCC v8", "Stage IIIA Bladder Cancer AJCC v8" ], "interventions": [ { "name": "Non-Interventional Study", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2026-06-29", "completion_date": "2027-01-31", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-10-14T15:16:51.052Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT07726602" }, { "nct_id": "NCT06605404", "title": "Pan-tumor MRD Study", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Muscle Invasive Bladder Urothelial Carcinoma", "Esophageal Cancer", "Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma", "Melanoma (Skin Cancer)", "NSCLC (Non-small Cell Lung Cancer)", "Pancreatic (Exocrine Only)", "Mix of Solid Tumors (MOST)" ], "interventions": [ { "name": "blood and tissue samples", "type": "DIAGNOSTIC_TEST" }, { "name": "blood and tissue samples", "type": "OTHER" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "OTHER" ], "sponsor": "Paradigm Health", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1350, "start_date": "2025-01-08", "completion_date": "2032-04", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-10-14T15:16:51.052Z", "location_count": 47, "location_summary": "Birmingham, Alabama • Bullhead City, Arizona • Casa Grande, Arizona + 43 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bullhead City", "state": "Arizona" }, { "city": "Casa Grande", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06605404" }, { "nct_id": "NCT06396533", "title": "Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Urothelial Carcinoma", "Muscle Invasive Bladder Urothelial Carcinoma", "Non-Muscle Invasive Bladder Urothelial Carcinoma" ], "interventions": [], "intervention_types": [], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 92, "start_date": "2024-08-13", "completion_date": "2029-02-23", "has_results": false, "last_update_posted_date": "2025-10-31", "last_synced_at": "2026-10-14T15:16:51.052Z", "location_count": 2, "location_summary": "Omaha, Nebraska • Philadelphia, Pennsylvania", "locations": [ { "city": "Omaha", "state": "Nebraska" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06396533" }, { "nct_id": "NCT02621151", "title": "Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Muscle-invasive Urothelial Cancer of the Bladder" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Transurethral Resection of Bladder Tumor", "type": "PROCEDURE" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "External Beam Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG", "RADIATION" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2016-08-11", "completion_date": "2025-12-15", "has_results": true, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-14T15:16:51.052Z", "location_count": 5, "location_summary": "Chicago, Illinois • Ann Arbor, Michigan • New York, New York + 1 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02621151" } ] }